《大行報告》美銀證券上調國藥控股(01099.HK)目標價至18.9元 評級「跑輸大市」
美銀證券發表報告指,國藥控股(01099.HK)去年訂單總收入按年升6%至5,521億元人民幣,而應佔淨利潤按年增9.9%至85億元人民幣;同時去年應收賬款周轉日數增加了2天至113日,而收款日數增加了1天至58日。
該行將公司今年、明年及2025年收入預測分別下調3%、4%及4%,主要是分銷方面放緩;因營運效率提高,該行亦下調了今年、明年及2025年的行政支出預測。
該行指,將公司今年、明年及2025年每股盈測分別調整為2.8%、2.2%及降1.4%,並將其目標價由16元上調至18.9元,重申其評級為「跑輸大市」。(ca/k)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.